366 related articles for article (PubMed ID: 38672732)
1. Role of Immune Cells and Immunotherapy in Multiple Myeloma.
Radhakrishnan V; Golla U; Kudva AK
Life (Basel); 2024 Apr; 14(4):. PubMed ID: 38672732
[TBL] [Abstract][Full Text] [Related]
2. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
3. Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma.
Swamydas M; Murphy EV; Ignatz-Hoover JJ; Malek E; Driscoll JJ
J Hematol Oncol; 2022 Feb; 15(1):17. PubMed ID: 35172851
[TBL] [Abstract][Full Text] [Related]
4. The Immune Microenvironment in Multiple Myeloma: Friend or Foe?
Lopes R; Caetano J; Ferreira B; Barahona F; Carneiro EA; João C
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33562441
[TBL] [Abstract][Full Text] [Related]
5. Revised International Staging System (R-ISS) stage-dependent analysis uncovers oncogenes and potential immunotherapeutic targets in multiple myeloma (MM).
Zhong L; Hao P; Zhang Q; Jiang T; Li H; Xiao J; Li C; Luo L; Xie C; Hu J; Wang L; Liu Y; Shi Y; Zhang W; Gong B
Elife; 2022 Oct; 11():. PubMed ID: 36315425
[TBL] [Abstract][Full Text] [Related]
6. Role of the bone marrow microenvironment in multiple myeloma treatment using CAR-T therapy.
Yao H; Cheng L; Chen D; Zhang Q; Qiu L; Ren SH; Dou BT; Wang H; Huang J; Fan FY
Expert Rev Anticancer Ther; 2023; 23(8):807-815. PubMed ID: 37343305
[TBL] [Abstract][Full Text] [Related]
7. The immune microenvironment of myeloma.
Noonan K; Borrello I
Cancer Microenviron; 2011 Dec; 4(3):313-23. PubMed ID: 21866321
[TBL] [Abstract][Full Text] [Related]
8. Actors on the Scene: Immune Cells in the Myeloma Niche.
Leone P; Solimando AG; Malerba E; Fasano R; Buonavoglia A; Pappagallo F; De Re V; Argentiero A; Silvestris N; Vacca A; Racanelli V
Front Oncol; 2020; 10():599098. PubMed ID: 33194767
[TBL] [Abstract][Full Text] [Related]
9. Role of the Immune Response in Disease Progression and Therapy in Multiple Myeloma.
Lee SJ; Borrello I
Cancer Treat Res; 2016; 169():207-225. PubMed ID: 27696265
[TBL] [Abstract][Full Text] [Related]
10. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.
Podar K; Jager D
Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977
[TBL] [Abstract][Full Text] [Related]
11. Good Cop, Bad Cop: Profiling the Immune Landscape in Multiple Myeloma.
Sharma NS; Choudhary B
Biomolecules; 2023 Nov; 13(11):. PubMed ID: 38002311
[TBL] [Abstract][Full Text] [Related]
12. The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression.
García-Ortiz A; Rodríguez-García Y; Encinas J; Maroto-Martín E; Castellano E; Teixidó J; Martínez-López J
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33435306
[TBL] [Abstract][Full Text] [Related]
13. Deregulation of Adaptive T Cell Immunity in Multiple Myeloma: Insights Into Mechanisms and Therapeutic Opportunities.
Leblay N; Maity R; Hasan F; Neri P
Front Oncol; 2020; 10():636. PubMed ID: 32432039
[TBL] [Abstract][Full Text] [Related]
14. Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1.
Tai YT; Cho SF; Anderson KC
Front Immunol; 2018; 9():1822. PubMed ID: 30147691
[TBL] [Abstract][Full Text] [Related]
15. Immune dysregulation in multiple myeloma: the current and future role of cell-based immunotherapy.
Russell BM; Avigan DE
Int J Hematol; 2023 May; 117(5):652-659. PubMed ID: 36964840
[TBL] [Abstract][Full Text] [Related]
16. The Leading Role of the Immune Microenvironment in Multiple Myeloma: A New Target with a Great Prognostic and Clinical Value.
Desantis V; Savino FD; Scaringella A; Potenza MA; Nacci C; Frassanito MA; Vacca A; Montagnani M
J Clin Med; 2022 Apr; 11(9):. PubMed ID: 35566637
[TBL] [Abstract][Full Text] [Related]
17. Predicting the impact of combined therapies on myeloma cell growth using a hybrid multi-scale agent-based model.
Ji Z; Su J; Wu D; Peng H; Zhao W; Nlong Zhao B; Zhou X
Oncotarget; 2017 Jan; 8(5):7647-7665. PubMed ID: 28032590
[TBL] [Abstract][Full Text] [Related]
18. Multiple Myeloma and the Immune Microenvironment.
Kawano Y; Roccaro AM; Ghobrial IM; Azzi J
Curr Cancer Drug Targets; 2017; 17(9):806-818. PubMed ID: 28201978
[TBL] [Abstract][Full Text] [Related]
19. Therapeutics to harness the immune microenvironment in multiple myeloma.
Ignatz-Hoover JJ; Driscoll JJ
Cancer Drug Resist; 2022; 5(3):647-661. PubMed ID: 36176763
[TBL] [Abstract][Full Text] [Related]
20. Different evasion strategies in multiple myeloma.
Wang C; Wang W; Wang M; Deng J; Sun C; Hu Y; Luo S
Front Immunol; 2024; 15():1346211. PubMed ID: 38464531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
